You are here » Home » Companies » Company Overview » Natco Pharma Ltd

Natco Pharma Ltd.

BSE: 524816 Sector: Health care
NSE: NATCOPHARM ISIN Code: INE987B01026
BSE LIVE 15:53 | 17 Aug 772.60 772.60
(%)
OPEN

770.00

HIGH

786.95

LOW

765.35

NSE 15:58 | 17 Aug 772.55 9.10
(1.19%)
OPEN

770.50

HIGH

786.70

LOW

765.00

OPEN 770.00
PREVIOUS CLOSE 0.00
VOLUME 44014
52-Week high 1080.00
52-Week low 495.00
P/E 24.88
Mkt Cap.(Rs cr) 13,466
Buy Price 0.00
Buy Qty 0.00
Sell Price 772.60
Sell Qty 46.00
OPEN 770.00
CLOSE 0.00
VOLUME 44014
52-Week high 1080.00
52-Week low 495.00
P/E 24.88
Mkt Cap.(Rs cr) 13,466
Buy Price 0.00
Buy Qty 0.00
Sell Price 772.60
Sell Qty 46.00

Natco Pharma Ltd. (NATCOPHARM) - Company History

Incorporated in Sep.'81 as Natco Fine Pharmaceutical Ltd, it became a deemed public company with effect from Jul.'92 and in Feb.'93, it changed its name to Natco Pharma (NPL). NPL began to manufacture conventional and time-release dosage forms of life-saving drugs. NPL is a contract manufacturer for reputed companies like Ranbaxy and Parke Davis. It has also obtained the coveted ISO 9002 certification, which will boost exports. It has initiated registration proceedings (for its formulations) in over 20 countries. To channelise its operations in the US, NPL has formed a new subsidiary, Natco Pharma, US. It has entered into research collaborations with Regional Research Laboratories, Jammu, for keto-L-gluconic acid (a penultimate for iso-ascorbic acid), with the Centre for Cellular & Molecular Biology for synthetic peptides and with the Central Leather Research Institute for oral vaccines. The company has introduced drugs like diltiazem, mononitrate, etc, in time-release form. Natco Laboratories, Natco Parenterals and Karanth Pharmaceuticals have merged with the flagship company, NPL to capitalise on the opportunities in the post-GATT era, to provide a large asset base and to increase high-technology capability. During 1995-96, NPL has implemented the project for formulations in the US. As a part of its diversification plans, the company is participating in the development of Krishnapatnam Industrial Port City Project, Nellore District, in collaboration with ITOCHU, Japan; Flour Daniels, USA; and HAM, Netherlands to create infrastructure. During 1996-97, the company entered into a agreement whereby Ranbaxy Laboratories (RLL) acquires rights in marketing certain NPL's products in Russia, Ukraine and other countries of CIS. Krishnapatnam Port Project has succeeded in signinig up with the UK based Indo British Port Development Consortium to develop the project. Natco is a minority participant in this project. The Andhra Pradesh government has extended the time allowed for time closure of Krishnapatnam Port project by another 2 years. The project is now proposed to be developed in 2 phases. In the first phase,it proposed to contrct 2 berths-one for loading and another for unloading. This facility is expected to be operational by August/September,2002 and thereafter,lighterage operations could commence.